Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eyad Nashawati

Critical Care Medicine Canton, OH Medical Doctor

NPI 1619970563 CMS profile 978898

2600 Tuscarawas St W, Ste 100, Canton, OH 44708

Open in the dashboard

General payments

$937

28 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eyad Nashawati of Canton, OH is reported in the CMS Open Payments database as having received $937 across 28 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 64th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $71 4
2024 General $137 6
2023 General $473 10
2022 General $185 3
2021 General $24 2
2020 General $35 2
2019 General $13 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eyad Nashawati
  • Critical Care Medicine median
  • Middle half of Critical Care Medicine
  • National median

In program year 2025, general payments to Eyad Nashawati were reported at $71. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.

Show as a table
Year Eyad Nashawati Critical Care Medicine median Middle half National median
2019 $13 $149 $51–$535 $163
2020 $35 $110 $30–$325 $114
2021 $24 $125 $34–$403 $132
2022 $185 $157 $49–$582 $149
2023 $473 $162 $56–$621 $160
2024 $137 $168 $53–$634 $164
2025 $71 $189 $59–$844 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Inspire Medical Systems, Inc. $334 5 payments
  2. Genzyme Corporation $127 4 payments
  3. AstraZeneca Pharmaceuticals LP $112 8 payments
  4. Regeneron Healthcare Solutions, Inc. $104 2 payments
  5. Sanofi-Aventis U.S. LLC $89 1 payment
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $49 2 payments
  7. GlaxoSmithKline, LLC. $35 2 payments
  8. Teva Pharmaceuticals USA, Inc. $29 1 payment
  9. Avadel CNS Pharmaceuticals, LLC $24 1 payment
  10. Novartis Pharmaceuticals Corporation $20 1 payment
  11. Other $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $837 26 payments
  2. Education $101 2 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $216 5 payments
  2. INSPIRE $192 4 payments
  3. Inspire Upper Airway Stimulation System $141 1 payment
  4. DUPIXENT Inflammation And Immunology $104 2 payments
  5. FASENRA Respiratory $61 4 payments
  6. FASENRA Respiratory $28 2 payments
  7. LUMRYZ $24 1 payment
  8. BREZTRI $24 2 payments
  9. NUCALA $21 1 payment
  10. XOLAIR $20 1 payment
  11. Other $28 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

2,379

Median for Critical Care (Intensivists): 406

Drug cost

$1,181,120

Median for Critical Care (Intensivists): $197,260

Branded share of claims

67.1%

Median for Critical Care (Intensivists): 69%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 29 $380,491
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 310 $251,636
Xywav Sodium,calcium,mag,pot Oxybate Brand 13 $176,368
Breo Ellipta Fluticasone/Vilanterol Brand 194 $88,493
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 127 $73,586
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 56 $49,790
Spiriva Respimat Tiotropium Bromide Brand 74 $44,941
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 26 $15,504
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 12 $10,748
Symbicort Budesonide/Formoterol Fumarate Brand 40 $10,620

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,531 Part D prescribers listed as Critical Care (Intensivists); they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$69,902

Medicare's payments for the services billed

Medicare patients

357

Average age 73

Services billed

905

161 women, 196 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 63%
Ischemic heart disease 53%
COPD 49%
Heart failure 47%
Chronic kidney disease 43%
Diabetes 42%
Atrial fibrillation 40%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $89
$89 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $31
$31 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

28 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Critical Care Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record